Can insufficient EPA delivery leave arachidonic-acid signaling relatively dominant?

EPA and arachidonic acid (AA) are shared substrates within membrane phospholipids and lipid-mediator pathways. The central mechanism is well established; the stronger causal evidence concerns what happens when EPA is increased, rather than proving that naturally low EPA alone produces a clinically defined AA-dominant state.

Membrane and mediator evidence

• EPA competes with AA for capacity-limited phospholipid remodeling and incorporation. In supplementation studies, this shifts membrane composition: 5 g/day EPA-rich oil for 12 weeks lowered the erythrocyte AA:EPA ratio from approximately 15:1 to 4:1. In an EPA+DHA dose-response trial, erythrocyte AA fell from 16.10% with placebo to 13.58% at 1,800 mg/day.
• Competition is particularly direct for platelet COX-1 and 12-LOX. With EPA and AA presented at a 1:1 ratio in washed human platelets, AA-associated thromboxane-related products, 12-HETE, and HHT decreased by about 50%, while EPA-derived products were formed.

Mechanistic consequences

• The result is a change in mediator identity, not merely reduced eicosanoid production. EPA can generate TXA3 rather than AA-derived TXA2; TXA3 is substantially less platelet-aggregatory and vasoconstrictive.
• Human trials report increased EPA-derived 12-HEPE, 18-HEPE, PGE3, and E-series resolvins, alongside lower skin PGE2 and reduced AA-derived COX prostaglandin metabolites. Thus, higher EPA availability can shift COX, LOX, and CYP-derived mediator profiles toward EPA products and specialized pro-resolving-mediator precursors.

Interpretation

• Effects vary by tissue, inflammatory stimulus, enzyme isoform, substrate ratio, and concurrent DHA exposure. AA-derived mediators are not uniformly harmful; their functions are context-specific.
• Bottom line: The claim is scientifically sound for EPA–AA competition in membranes and mediator-generating enzymes. It is biologically plausible that insufficient EPA favors relative AA signaling, but direct evidence that low endogenous EPA alone causes an AA-dominant signaling state in humans remains limited.